Sökning: WFRF:(Henrohn Dan) >
Societal economic b...
Societal economic burden and determinants of costs for atopic dermatitis
-
- Ortsäter, Gustaf (författare)
- Quantify Research, Stockholm, Sweden,Quantify Research AB
-
- De Geer, Anna (författare)
- Pfizer AB, Sollentuna, Sweden,Pfizer Inc. US
-
- Rieem Dun, Alexander (författare)
- Quantify Research, Stockholm, Sweden,Quantify Research AB
-
visa fler...
-
- Geale, Kirk (författare)
- Umeå University,Umeå universitet,Dermatologi och venereologi,Quantify Research, Stockholm, Sweden; Dermatology and Venerology, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden
-
- Lindberg, Ingrid (författare)
- Quantify Research, Stockholm, Sweden,Quantify Research AB
-
- Thyssen, Jacob Pontoppidan (författare)
- Department of Dermatology and Venereology, Bispebjerg Hospital, University of Copenhagen, Hellerup, Denmark
-
- von Kobyletzki, Laura B. (författare)
- Lund University,Lunds universitet,Yrkes- och miljödermatologi,Forskargrupper vid Lunds universitet,Occupational and Environmental Dermatology,Lund University Research Groups,Skåne University Hospital
-
- Metsini, Alexandra, 1976- (författare)
- Örebro University,Örebro universitet,Institutionen för medicinska vetenskaper,Institute of Medical Sciences, University of Örebro, Örebro, Sweden
-
- Henrohn, Dan (författare)
- Uppsala University
-
- Neregård, Petra (författare)
- Pfizer AB, Sollentuna, Sweden
-
- Cha, Amy (författare)
- Pfizer Inc., NY, New York, United States,Pfizer Inc., New York, New York, USA
-
- Cappelleri, Joseph C. (författare)
- Pfizer Inc., NY, New York, United States,Pfizer Inc., New York, New York, USA
-
- Romero, William (författare)
- Inflammation & Immunology, Pfizer Ltd., London, United Kingdom,Inflammation & Immunology, PfizerLtd., London, UK,Pfizer Limited, UK
-
- Neary, Maureen P. (författare)
- Pfizer Inc., NY, New York, United States,Pfizer Inc., New York, New York, USA
-
visa färre...
-
(creator_code:org_t)
- 2022-11-23
- 2022
- Engelska.
-
Ingår i: JEADV Clinical Practice. - : John Wiley & Sons. - 2768-6566. ; 1:4, s. 326-343
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://umu.diva-por... (primary) (Raw object)
-
http://dx.doi.org/10... (free)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
https://lup.lub.lu.s...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Atopic dermatitis (AD) is a common inflammatory skin disease while the economic burden of AD by severity is not adequately understood.Objective: To estimate the societal economic burden and to identify cost determinants of AD.Methods: In this population-based, controlled cohort study in Sweden, patients with AD were identified through diagnosis codes in primary or secondary care or by dispensed medications using administrative healthcare registers. A reference cohort without AD was randomly selected from the general population. Healthcare costs (primary/secondary care visits and dispensed medication) and indirect costs (care for sick children and long-term sick leave for adults) were calculated annually. AD patients were stratified by age (paediatric [age < 12], adolescent [12 ≤ age < 18] or adult [age ≥ 18]), and severity (mild-to-moderate [M2M] or severe AD) and matched to the reference cohort.Results: Compared with controls, the annual mean per-patient direct healthcare costs in the first year following diagnosis were €941 and €1259 higher in paediatric patients with M2M and severe AD, respectively. In the first year following diagnosis, the mean indirect cost for care of sick children was €69 and €78 higher per patient in M2M and severe AD, respectively. In adolescents with M2M and severe AD, direct healthcare costs were €816 and €1260 higher, respectively. In adults, healthcare costs were €1583 and €2963 higher in patients with M2M and severe AD, respectively and indirect costs were €148 and €263 higher compared with controls. Management of comorbid medical conditions was an important driver of incremental healthcare costs. Total incremental societal economic burden for AD was €351 and €96 million higher in patients with M2M and severe AD, respectively, compared to controls.Conclusion: AD is associated with a significant societal economic burden primarily driven by the cost burden of M2M AD due to the high prevalence of this population. Regardless of severity level, management of non-AD comorbidities is a major driver of total costs.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Dermatologi och venereologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Dermatology and Venereal Diseases (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Hälsovetenskap -- Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Health Sciences -- Health Care Service and Management, Health Policy and Services and Health Economy (hsv//eng)
Nyckelord
- atopic dermatitis
- economic burden
- eczema
- epidemiology
- healthcare costs
- indirect costs
- public health research
- atopic dermatitis
- economic burden
- eczema
- epidemiology
- healthcare costs
- indirect costs
- public health research
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Ortsäter, Gustaf
-
De Geer, Anna
-
Rieem Dun, Alexa ...
-
Geale, Kirk
-
Lindberg, Ingrid
-
Thyssen, Jacob P ...
-
visa fler...
-
von Kobyletzki, ...
-
Metsini, Alexand ...
-
Henrohn, Dan
-
Neregård, Petra
-
Cha, Amy
-
Cappelleri, Jose ...
-
Romero, William
-
Neary, Maureen P ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Dermatologi och ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Hälsovetenskap
-
och Hälso och sjukvå ...
- Artiklar i publikationen
-
JEADV Clinical P ...
- Av lärosätet
-
Umeå universitet
-
Örebro universitet
-
Lunds universitet